Breaking News

US Department of Labor releases informational copies of 2022 Form 5500 Series Annual Return/Report Two Men Wanted on Charges of Aggravated Sex Crimes Nabbed at the Progreso Port of Entry Secretary Walsh announces new partners, action plan, support for international worker voice initiative False Name Turns into Counterfeit U.S. Currency Discovery by Wellesley Island Border Patrol Agents US Department of Labor awards $5M to help fight workplace discrimination, harassment; empower working women in Nigeria, Liberia El Paso CBP Officers Apprehend Fugitive Wanted for Homicide US Department of Labor recovers more than $17K for illegally terminated employee after Publix Super Markets Inc. violates medical leave protections CBP Seizes Fentanyl and Methamphetamine at Presidio Port

Issued: London UK

The U.S. Food and Drug Administration (FDA) today posted a comprehensive review conducted by GlaxoSmithKline (GSK) of the cardiovascular safety data on Avandia® (rosiglitazone maleate). GSK’s review supports the overall positive benefit-risk profile of rosiglitazone as an important medicine for patients with type 2 diabetes.

The data in GSK’s review come from meta-analyses, observational studies and large controlled clinical trials that have become available since July 2007, when the FDA convened advisory committees to review the efficacy and safety of rosiglitazone. The FDA’s Endocrinologic and Metabolic Drugs, and the Drug Safety and Risk Management Advisory Committees will review these data at a meeting on 13-14 July 2010.

“Since 2007 we have seen results from six controlled clinical trials looking at the cardiovascular safety of Avandia and together they show that this medicine does not increase the overall risk of heart attack, stroke or death,” said Dr. Murray Stewart, Vice President for Clinical Development at GSK. “We also know that Avandia lowers glucose levels in both the short- and long-term and is the only oral anti-diabetic medicine that has been shown to sustain blood sugar control for up to five years.[1] We look forward to presenting these data and participating in a rigorous scientific discussion with the advisory committees.”

About nine percent of adults in the U.S. have type 2 diabetes, which has increased from five percent in 1997 (Ref CDC website). Type 2 diabetes is characterised by high blood sugar levels and it represents a major health risk with complications that can include blindness, kidney failure, amputations, heart attack and stroke.

A three-page executive summary of GSK’s briefing document for the FDA meeting and a copy of the complete briefing document is posted on the FDA’s website.

[1] Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355(23):2427-2443.

GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit or the Avandia resource centre.

GlaxoSmithKline Enquiries:


UK Media enquiries:

Philip Thomson
Claire Brough
Stephen Rea
Alexandra Harrison
Jo Revill

(020) 8047 5502
(020) 8047 5502
(020) 8047 5502
(020) 8047 5502
(020) 8047 5502




US Media enquiries:

Nancy Pekarek
Mary Anne Rhyne
Kevin Colgan
Sarah Alspach

(919) 483 2839
(919) 483 2839
(919) 483 2839
(919) 483 2839



European Analyst/
Investor enquiries:

David Mawdsley
Sally Ferguson
Gary Davies

(020) 8047 5564
(020) 8047 5543
(020) 8047 5503


US Analyst/
Investor enquiries:

Tom Curry
Jen Hill Baxter

(215) 751 5419
(215) 751 7002

Source link